Compass Therapeutics (CMPX) EBITDA: 2023-2025
Historic EBITDA for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$14.2 million.
- Compass Therapeutics' EBITDA fell 43.31% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.0 million, marking a year-over-year decrease of 40.93%. This contributed to the annual value of -$49.2 million for FY2024, which is 16.72% down from last year.
- Per Compass Therapeutics' latest filing, its EBITDA stood at -$14.2 million for Q3 2025, which was up 28.55% from -$19.9 million recorded in Q2 2025.
- Compass Therapeutics' 5-year EBITDA high stood at -$7.7 million for Q1 2023, and its period low was -$19.9 million during Q2 2025.
- For the 3-year period, Compass Therapeutics' EBITDA averaged around -$12.9 million, with its median value being -$12.9 million (2023).
- Data for Compass Therapeutics' EBITDA shows a maximum YoY tumbled of 52.58% (in 2025) over the last 5 years.
- Compass Therapeutics' EBITDA (Quarterly) stood at -$12.9 million in 2023, then dropped by 18.23% to -$15.3 million in 2024, then crashed by 43.31% to -$14.2 million in 2025.
- Its last three reported values are -$14.2 million in Q3 2025, -$19.9 million for Q2 2025, and -$16.7 million during Q1 2025.